FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208824903> ?p ?o ?g. }

• W3208824903 endingPage "S35" @default.
• W3208824903 startingPage "S35" @default.
• W3208824903 abstract "Purpose/Objective(s)We recently published 2-year results of the prospective, randomized IMRT-MC2 trial, showing non-inferior local control and cosmesis in breast cancer patients after conventionally fractionated intensity-modulated radiotherapy with simultaneously integrated boost (IMRT-SIB), compared to 3D-conformal radiotherapy with sequential boost (3D-CRT-seqB). The present study reports on 2-year quality of life results.Materials/MethodsFive hundred two patients were enrolled to analyze non-inferiority of IMRT-SIB (50.4 Gy in 1.8 Gy fractions with a 64.4 Gy SIB to the tumor bed in 2.3 Gy fractions) to 3D-CRT-seqB (50.4 Gy in 1.8 Gy fractions, followed by a sequential boost of 16 Gy in 2 Gy fractions). For quality of life (QoL) assessment, patients completed the QLQ-C30 (15 items) and QLQ-BR23 (8 items) questionnaires at baseline and 6 weeks and 2 years after radiotherapy. Comparisons between treatment groups were made at 6 weeks and 2 years after radiotherapy, using Mann-Whitney U-test. The Friedmann test was used to compare QoL at different time points during follow-up (baseline, 6 weeks and 2 years after radiotherapy) and to detect significant changes of QoL over all time points.ResultsAfter six weeks and two years, 237 and 212 QoL questionnaires (94 % and 84 %) were available in the IMRT group, 231 and 210 (93 % and 84 %) in the control group, respectively. The only significant difference of QoL scores between the IMRT-SIB and the 3-D-CRT-seqB group was seen 6 weeks after radiotherapy for pain (22.3 points for IMRT vs. 27.0 points for 3D-CRT-seqB; P = 0.033; r = 0.102) and for arm symptoms (18.1 points for IMRT vs. 23.6 points for 3D-CRT-seqB; P = 0.013; r = 0.118), both favoring IMRT. Looking at changes after two years compared to baseline, both arms showed significant improvement in global score (IMRT: P = 0.009, r = 0.021; 3D-CRT: P = 0.001, r = 0.028) with slight deterioration on the role (IMRT: P = 0.008, r = 0.021; 3-D-CRT: P = 0.001, r = 0.038) and social functioning (IMRT: P = 0.013, r = 0.021; 3D-CRT: P = 0.001, r = 0.033) as well as the future perspectives scale (IMRT: P = 0.003, r = 0.026; 3D-CRT: P = 0.0034, r = 0.020).ConclusionThis is the first randomized phase III trial demonstrating that simultaneously integrated boost irradiation was associated with slightly superior quality of life compared to conventional sequential boost irradiation. These findings further support the widely clinical implementation of SIB in adjuvant breast cancer treatment. NCT01322854 We recently published 2-year results of the prospective, randomized IMRT-MC2 trial, showing non-inferior local control and cosmesis in breast cancer patients after conventionally fractionated intensity-modulated radiotherapy with simultaneously integrated boost (IMRT-SIB), compared to 3D-conformal radiotherapy with sequential boost (3D-CRT-seqB). The present study reports on 2-year quality of life results. Five hundred two patients were enrolled to analyze non-inferiority of IMRT-SIB (50.4 Gy in 1.8 Gy fractions with a 64.4 Gy SIB to the tumor bed in 2.3 Gy fractions) to 3D-CRT-seqB (50.4 Gy in 1.8 Gy fractions, followed by a sequential boost of 16 Gy in 2 Gy fractions). For quality of life (QoL) assessment, patients completed the QLQ-C30 (15 items) and QLQ-BR23 (8 items) questionnaires at baseline and 6 weeks and 2 years after radiotherapy. Comparisons between treatment groups were made at 6 weeks and 2 years after radiotherapy, using Mann-Whitney U-test. The Friedmann test was used to compare QoL at different time points during follow-up (baseline, 6 weeks and 2 years after radiotherapy) and to detect significant changes of QoL over all time points. After six weeks and two years, 237 and 212 QoL questionnaires (94 % and 84 %) were available in the IMRT group, 231 and 210 (93 % and 84 %) in the control group, respectively. The only significant difference of QoL scores between the IMRT-SIB and the 3-D-CRT-seqB group was seen 6 weeks after radiotherapy for pain (22.3 points for IMRT vs. 27.0 points for 3D-CRT-seqB; P = 0.033; r = 0.102) and for arm symptoms (18.1 points for IMRT vs. 23.6 points for 3D-CRT-seqB; P = 0.013; r = 0.118), both favoring IMRT. Looking at changes after two years compared to baseline, both arms showed significant improvement in global score (IMRT: P = 0.009, r = 0.021; 3D-CRT: P = 0.001, r = 0.028) with slight deterioration on the role (IMRT: P = 0.008, r = 0.021; 3-D-CRT: P = 0.001, r = 0.038) and social functioning (IMRT: P = 0.013, r = 0.021; 3D-CRT: P = 0.001, r = 0.033) as well as the future perspectives scale (IMRT: P = 0.003, r = 0.026; 3D-CRT: P = 0.0034, r = 0.020). This is the first randomized phase III trial demonstrating that simultaneously integrated boost irradiation was associated with slightly superior quality of life compared to conventional sequential boost irradiation. These findings further support the widely clinical implementation of SIB in adjuvant breast cancer treatment. NCT01322854" @default.
• W3208824903 created "2021-11-08" @default.
• W3208824903 creator A5000073064 @default.
• W3208824903 creator A5000911809 @default.
• W3208824903 creator A5001036242 @default.
• W3208824903 creator A5010170241 @default.
• W3208824903 creator A5036877691 @default.
• W3208824903 creator A5039811619 @default.
• W3208824903 creator A5047886047 @default.
• W3208824903 creator A5050549111 @default.
• W3208824903 creator A5057528043 @default.
• W3208824903 creator A5059359126 @default.
• W3208824903 creator A5059687210 @default.
• W3208824903 creator A5062124261 @default.
• W3208824903 creator A5064469867 @default.
• W3208824903 creator A5067246293 @default.
• W3208824903 creator A5072077397 @default.
• W3208824903 creator A5077923178 @default.
• W3208824903 creator A5083825941 @default.
• W3208824903 creator A5084545133 @default.
• W3208824903 date "2021-11-01" @default.
• W3208824903 modified "2023-09-27" @default.
• W3208824903 title "Quality of Life After Simultaneously Integrated Boost With Intensity-Modulated vs. Conventional Radiotherapy Followed by Sequential Boost for Adjuvant Treatment of Breast Cancer: 2-Year Results of the Multicenter Randomized IMRT-MC2 Trial" @default.
• W3208824903 doi "https://doi.org/10.1016/j.ijrobp.2021.07.105" @default.
• W3208824903 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700540" @default.
• W3208824903 hasPublicationYear "2021" @default.
• W3208824903 type Work @default.
• W3208824903 sameAs 3208824903 @default.
• W3208824903 citedByCount "0" @default.
• W3208824903 crossrefType "journal-article" @default.
• W3208824903 hasAuthorship W3208824903A5000073064 @default.
• W3208824903 hasAuthorship W3208824903A5000911809 @default.
• W3208824903 hasAuthorship W3208824903A5001036242 @default.
• W3208824903 hasAuthorship W3208824903A5010170241 @default.
• W3208824903 hasAuthorship W3208824903A5036877691 @default.
• W3208824903 hasAuthorship W3208824903A5039811619 @default.
• W3208824903 hasAuthorship W3208824903A5047886047 @default.
• W3208824903 hasAuthorship W3208824903A5050549111 @default.
• W3208824903 hasAuthorship W3208824903A5057528043 @default.
• W3208824903 hasAuthorship W3208824903A5059359126 @default.
• W3208824903 hasAuthorship W3208824903A5059687210 @default.
• W3208824903 hasAuthorship W3208824903A5062124261 @default.
• W3208824903 hasAuthorship W3208824903A5064469867 @default.
• W3208824903 hasAuthorship W3208824903A5067246293 @default.
• W3208824903 hasAuthorship W3208824903A5072077397 @default.
• W3208824903 hasAuthorship W3208824903A5077923178 @default.
• W3208824903 hasAuthorship W3208824903A5083825941 @default.
• W3208824903 hasAuthorship W3208824903A5084545133 @default.
• W3208824903 hasBestOaLocation W32088249031 @default.
• W3208824903 hasConcept C121608353 @default.
• W3208824903 hasConcept C126322002 @default.
• W3208824903 hasConcept C141071460 @default.
• W3208824903 hasConcept C159110408 @default.
• W3208824903 hasConcept C168563851 @default.
• W3208824903 hasConcept C203092338 @default.
• W3208824903 hasConcept C2779951463 @default.
• W3208824903 hasConcept C2780943399 @default.
• W3208824903 hasConcept C2989005 @default.
• W3208824903 hasConcept C509974204 @default.
• W3208824903 hasConcept C530470458 @default.
• W3208824903 hasConcept C71924100 @default.
• W3208824903 hasConceptScore W3208824903C121608353 @default.
• W3208824903 hasConceptScore W3208824903C126322002 @default.
• W3208824903 hasConceptScore W3208824903C141071460 @default.
• W3208824903 hasConceptScore W3208824903C159110408 @default.
• W3208824903 hasConceptScore W3208824903C168563851 @default.
• W3208824903 hasConceptScore W3208824903C203092338 @default.
• W3208824903 hasConceptScore W3208824903C2779951463 @default.
• W3208824903 hasConceptScore W3208824903C2780943399 @default.
• W3208824903 hasConceptScore W3208824903C2989005 @default.
• W3208824903 hasConceptScore W3208824903C509974204 @default.
• W3208824903 hasConceptScore W3208824903C530470458 @default.
• W3208824903 hasConceptScore W3208824903C71924100 @default.
• W3208824903 hasIssue "3" @default.
• W3208824903 hasLocation W32088249031 @default.
• W3208824903 hasLocation W32088249032 @default.
• W3208824903 hasOpenAccess W3208824903 @default.
• W3208824903 hasPrimaryLocation W32088249031 @default.
• W3208824903 hasRelatedWork W2055570731 @default.
• W3208824903 hasRelatedWork W2140859993 @default.
• W3208824903 hasRelatedWork W2195671413 @default.
• W3208824903 hasRelatedWork W2276162241 @default.
• W3208824903 hasRelatedWork W2887282919 @default.
• W3208824903 hasRelatedWork W2896934404 @default.
• W3208824903 hasRelatedWork W2955643247 @default.
• W3208824903 hasRelatedWork W3163371109 @default.
• W3208824903 hasRelatedWork W4224038774 @default.
• W3208824903 hasRelatedWork W4322772323 @default.
• W3208824903 hasVolume "111" @default.
• W3208824903 isParatext "false" @default.
• W3208824903 isRetracted "false" @default.
• W3208824903 magId "3208824903" @default.
• W3208824903 workType "article" @default.